Pipeline

We have a diverse pipeline designed to make a meaningful difference for patients

We have a diverse pipeline designed to make a meaningful difference for patients

Our growing development pipeline of innovative new therapies is driven by the flexibility of our TransCon® technologies and our aim to improve patients' lives. We have multiple prodrug therapies in development. Each candidate is unique and designed to be a best-in-class therapy.

Endocrinology Rare Diseases

Phase 1
Phase 2
Phase 3
TransCon hGH
Pediatric GHD
Japan1
Phase 3
Adult GHD
Global2
Phase 3
Turner Syndrome
U.S.3
Phase 2
TransCon PTH
Adult Hypoparathyroidism
U.S. & Europe4
Phase 3
Adult Hypoparathyroidism
Japan5
Phase 3
TransCon CNP
Achondroplasia
Global6
Phase 2

Oncology

Phase 1
Phase 2
Phase 3
TransCon TLR7/8 Agonist
Solid Tumors
Intratumoral7
Phase 2
TransCon IL-2 β/γ
Solid Tumors
Systemic8
Phase 1

Ophthalmology

Pre-Clinical
TransCon RBZ
Wet AMD
Pre-Clinical

1Japanese riGHt Trial
2 Global foresiGHt Trial
3New InsiGHTS Trial
4NDA submitted to the FDA; PDUFA action date April 30, 2023, EU MAA submitted November 2022, decision anticipated Q4 2023
5Japanese PaTHway Japan Trial
6Global ApproaCH Trial
7transcendIT-101 Trial. Includes four indication-specific cohorts currently enrolling patients.
8IL-βelieγe Trial

Explore

You are about to access www.ascendispharma.com. Click below if you wish to proceed.